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Abstract 
Genome-wide association studies (GWAS) have identified 45 single nucleotide 
polymorphisms (SNPs) associated with lung cancer. Only less than SNPs, small 
insertions and deletions (INDELs) are the second most abundant genetic 
polymorphisms in the human genome. INDELs are highly associated with multiple 
human diseases, including lung cancer. However, limited studies with large-scale 
samples have been available to systematically evaluate the effects of INDELs on lung 
cancer risk. Here, we performed a large-scale meta-analysis to evaluate INDELs and 
their risk for lung cancer in 23,202 cases and 19,048 controls. Functional annotations 
were performed to further explore the potential function of lung cancer risk INDELs. 
Conditional analysis was used to clarify the relationship between INDELs and SNPs. 
Four new risk loci were identified in genome-wide INDEL analysis (1p13.2: 
rs5777156, Insertion, OR = 0.92, P = 9.10×10-8; 4q28.2: rs58404727, Deletion, OR = 
1.19, P = 5.25×10-7; 12p13.31: rs71450133, Deletion, OR = 1.09, P = 8.83×10-7; and 
14q22.3: rs34057993, Deletion, OR = 0.90, P = 7.64×10-8). The eQTL analysis and 
functional annotation suggested that INDELs might affect lung cancer susceptibility 
by regulating the expression of target genes. After conducting conditional analysis on 
potential causal SNPs, the INDELs in the new loci were still nominally significant. 
Our findings indicate that INDELs could be potentially functional genetic variants for 
lung cancer risk. Further functional experiments are needed to better understand 
INDEL mechanisms in carcinogenesis. 
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Introduction 
Lung cancer is one of the most frequently diagnosed cancers and the leading 
cause of cancer mortality worldwide [1]. It is estimated that more than 1.8 million 
new lung cancer cases occurred in 2012, accounting for approximately 13% of total 
cancer diagnoses [2]. Although tobacco smoking is a major lung cancer risk factor, 
genetic factors also play an important role in lung carcinogenesis. According to 
previous studies, common SNPs can explain approximately 12% ~ 21% heritability 
in lung cancer in Asian and European populations [3,4]. Genome-wide association 
studies (GWAS) have previously identified 45 susceptibility loci associated with 
lung cancer [5], and single nucleotide polymorphisms (SNPs) in the CHRNA3, 
CHRNA5, TERT and human leukocyte antigen (HLA) regions showed consistent and 
robust associations in different studies.  
To date, the vast majority of studies have focused on the relationship between 
SNPs and lung cancer. Small insertions and deletions (INDELs), which are another 
type of variations, also play an important role in lung carcinogenesis. INDELs are 
defined as short insertions and deletions (ranging from 1 to 10,000 bp) in the human 
genome [6,7]. As important genetic variations, INDELs are the second most 
abundant genetic polymorphisms in the human genome, only less than SNPs [8]. The 
final phase of the 1000 Genomes Project has characterized more than 3.4 million 
INDELs in 88 million variant sites in the human genome, and compared with phase I, 
the number of INDELs increased by 70% [8]. This provides a comprehensive panel 
to explore the effects of INDELs. INDELs in the genome are highly associated with 
multiple human diseases; nearly 24% of Mendelian diseases are caused by INDELs 
based on the Human Gene Mutation Database (HGMD) [9]. Over the past decade, 
the development of high-throughput sequencing has made it possible to detect 
INDELs in individual genomes. Next-generation sequencing (NGS) analyses have 
identified INDELs across multiple cancer types [10,11]; however, these INDELs 
were at the somatic level with low frequency. At the germline level, INDELs have 
been described as associated with cancers in case-control studies by genotyping or 
genomic imputation. For example, a single INDEL in the 6q25.3 locus, which is 
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related to the SLC22A1 and SLC22A2 genes, increased the risk of prostate cancer in 
a multi-ethnic GWAS [12]. Another study in a Chinese population found that a 5-bp 
INDEL in the GAS5 gene increased hepatocellular carcinoma risk [13]. For lung 
cancer risk, Sun T et al. reported a six-nucleotide deletion variant in the CASP8 
promoter was related with reduced risk of multiple cancers, including lung cancer 
[PMID: 17450141]. In addition, Liu G et al. found two insertion variant in BRM 
promoter region were also associated with the increased risk of lung cancer [PMID: 
21478907]. However, limited studies with large-scale samples have been available to 
systematically evaluate the effects of INDELs on lung cancer risk. In this study, we 
aimed to investigate the relationship between INDELs and lung cancer risk at a 
genome-wide level. To accomplish this, we conducted a large-scale case-control 
study with 23,202 lung cancer cases and 19,048 controls to dissect the associations 
between INDELs and lung cancer risk among European and Asian populations. 
 
Material and Methods 
Study population 
In this study, we integrated three published lung cancer GWAS, including the 
TRICL-ILCCO OncoArray European data (The OncoArray Consortium lung cancer 
GWAS: 43,398 participants in total, European population) [14], the DCEG Lung 
Cancer Study (the National Cancer Institute lung cancer GWAS: 5,716 cases and 
5,821 controls, European population) [15], and our published NJMU GWAS data 
(Nanjing Medical University lung cancer GWAS from Nanjing and Beijing: 2,331 
cases and 3,077 controls, Chinese population) [16]. Briefly, for the TRICL-ILCCO 
OncoArray data, we used the same quality control strategies in the previous paper 
[14]. The DCEG Lung Cancer Study was applied from the Genotypes and 
Phenotypes (dbGAP) database (Project ID: phs000336.v1.p1) [15]. Considering the 
duplication of samples within the TRICL-ILCCO OncoArray data, 3,251 samples 
were removed when IBD (identity-by-descent) > 0.45. Consequently, 2,427 cases 
and 1,944 controls in the DCEG Lung Cancer Study were kept for further analysis. 
For the NJMU GWAS data, standard sample quality control strategies were also 
performed according to the original paper [16]. Finally, a total of 23,202 cases and 
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19,048 controls were included for further analysis (Table S1). Each study was 
approved by the local institutional review board. 
 
Genotype quality control and imputation 
The details of the imputation procedures used in the TRICL-ILCCO OncoArray 
project have been described previously [14,17]. Briefly, SHAPETIT V2 and 
IMPUTE2 were used for phasing and imputation, respectively. The 1000 Genomes 
Project Phase III database (released at October, 2014) was used as a reference dataset. 
After imputation, there were 1,857,403 INDELs in the TRICL-ILCCO OncoArray 
data. Then, we performed standard quality control on the imputed INDELs data by 
excluding the data with the following characteristics: (1) imputation quality INFO < 
0.9; (2) genotyping call rate < 95%; (3) minor allele frequency (MAF) in controls < 
0.01; or (4) Hardy-Weinberg equilibrium (HWE) <1×10-12 in cases or <1×10-7 in 
controls. We also excluded 17,812 INDELs located in genome segmental duplication 
regions [18], which may lead to inaccuracy during imputation. Thus, the total 
number of TRICL-ILCCO OncoArray INDELs was 694,395. For the DCEG GWAS 
and NJMU GWAS data, the imputation procedures have been previously described 
[19,20]. We conducted the same quality control criteria on the DCEG GWAS and 
NJMU GWAS imputation data. Finally, we obtained 484,196 overlapped INDELs 
for the subsequent analysis (Figure S1). 
 
eQTL and differential expression analysis  
We used the Genotype-Tissue Expression (GTEx) Project expression 
quantitative trait locus (eQTL) database (V7 release) for identified INDELs. We 
searched each INDEL-gene pair eQTL analysis result in lung tissue. Due to lack of 
information of INDEL rs71450133 in GTEx database, we use SNP rs28435996 
which showed high LD (r2 = 0.94) with rs71450133 as a tagging SNP. Differential 
expression analyses were performed using data from The Cancer Genome Atlas 
(TCGA) project [21,22]. A total of 106 paired lung tumor tissues and adjacent tissues 
from the TCGA database were used to performed differential expression analyses 
using Wilcoxon paired test.  
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In silico functional annotation and rank scoring system development 
We combined multiple sources of public functional annotation databases to 
explore the potential function of the INDELs, similar strategy was also applied in the 
recent largest breast cancer GWAS study with the INQUISIT algorithm [PMID: 
29059683]. Genomic regulatory region and functional score were used to evaluate 
INDELs and SNP showed high LD with them. Regulatory elements, including 
promoter, enhancer, and transcription factor binding sites (TFBS) data were based on 
the Encyclopedia of DNA Elements (ENCODE) Project A549 human lung cancer 
cell line data [23]. Four annotation database, including 3DSNP [24], Combined 
Annotation-Dependent Depletion (CADD) [25], Phenotype-Informed Noncoding 
Element Scoring (PINES) [26] and RegulomeDB [27] were also used to identify the 
potential pathogenicity and function of the INDELs. We developed a rank scoring 
system to integrate all these data together and INDELs identified in this study, as 
well as SNPs which showed a high LD (r2 > 0.6) relationship with INDELs were all 
annotated by this rank scoring system.  
We generated binary variables, feature rank, to represent importance of each 
variant in each database, 1 defined as more important and 0 defined as less important. 
For chromatin biofeatures data, as mentioned above, promoter, enhancer and TFBS, 
if INDELs or SNPs located in the regulatory region, the feature rank were defined as 
1, else as 0. For four annotation databases (3DSNP, CADD, PINES and 
RegulomeDB) with scores, if a variant’s score in the top 10% of corresponding 
INDEL LD block, the feature rank was defined as 1 (more important), otherwise it 
was defined as 0 (less important). Finally, all feature ranks of seven annotations were 
accumulated as a final score for each INDEL and SNP, ranging from 0 to 7. The 
variant with the highest score was considered as a potentially causal variant. 
 
Statistical analysis 
For the three GWAS studies, the association testing for each INDEL was 
performed using the SNPTEST (v2.5.4) software, which is based on a probabilistic 
dosage model adjusting for age, gender, and the first three principal components in 
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the TRICL-ILCCO OncoArray; age, gender, and the first principal component in the 
DCEG GWAS; and age, gender, pack-years, and the first principal component in the 
NJMU GWAS. Meta-analysis (fixed-effect model) was conducted to combine 
individual association estimates from the three GWAS datasets. Testing for 
differences in the genetic effects across the three studies was assessed by using the I2 
and P values calculated from Cochran’s Q statistic. Meta-analysis was conducted 
using the GWAMA software. Subgroup analysis was performed for baseline 
characteristics, including age, gender, histology, and smoke status. For the 
conditional analysis, a multivariate logistic regression model adjusting for age, 
gender, the first three principal components and known lung cancer risk variants was 
used with the TRICL-ILCCO OncoArray.  
General analyses were performed using the R software (version 3.3.1). P ≤ 0.05 
was used as the threshold of statistical significance and all statistical tests were 
two-sided. A suggestive threshold of 1.0×10-6 was used to present significant 
INDELs [PMID: 19915574, 23722424], bonferroni correction was also applied to 
account for multiple comparisons (threshold: 0.05/484,196 = 1.03×10-7).  
 
Results 
Study overview 
In this study, we imputed a total of 484,196 INDELs based on 23,202 lung 
cancer cases and 19,048 controls. Nineteen INDELs along with 11 loci were 
identified as being significantly associated with lung cancer risk at a suggestive 
threshold of 1.0×10-6 (Figure 1; Table 1; Table 2). Among them, four loci (1p13.2, 
4q28.2, 12p13.31 and 14q22.3) were novel risk loci for lung cancer, while seven of 
them have been previously reported as lung cancer risk loci as indicated by SNPs 
(5p15.33, 6p21.32, 6p21.33, 6p22.1, 6p22.2, 11q23.3 and 15q25.1). The results of 
INDELs in three studies were listed in Table S2. 
Four new risk loci were identified in our genome-wide INDEL analysis (Table 
1), including rs5777156 in 1p13.2 (Insertion, OR = 0.92, 95%CI = 0.89-0.95, P = 
9.10×10-8); rs58404727 in 4q28.2 (Deletion, OR = 1.19, 95%CI = 1.11-1.28, P = 
5.25×10-7); rs71450133 in 12p13.31 (Deletion, OR = 1.09, 95%CI = 1.05-1.13, P = 
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8.83×10-7); and rs34057993 in 14q22.3 (Deletion, OR = 0.90, 95%CI = 0.87-0.94, P 
= 7.64×10-8). INDELs rs5777156 and rs34057993 were still significant after 
Bonferroni correction (P < 1.03×10-7). There was no evidence of heterogeneity 
among the studies for the new risk loci. Subgroup analyses on the four new INDELs 
from the OncoArray data are summarized in Table S3. No evidence of heterogeneity 
was observed for the new risk loci among age, gender, smoking status, histology 
type and ethnicity, which implied the effects of the new risk loci were robust. 
 
INDELs in known lung cancer risk loci  
The results for 15 INDELs in known lung cancer risk loci are presented in Table 
2. At 15q25.1, a well-known lung cancer susceptibility locus related to nicotine 
addiction, INDELs harbored the lowest P value (rs577626090, Deletion, OR = 1.29, 
95%CI = 1.25-1.33, P = 9.91×10-64). INDELs also reached the significance threshold 
in 5p15.33 and the human leukocyte antigen (HLA) region. We validated the 
recently reported Oncoarray risk locus, which correlated with 11q23.3 in our 
analysis (rs139157129, Deletion, OR = 0.93, 95%CI =0.90-0.95, P = 1.90×10-7). 
INDELs in the known loci showed strong effects, and 10 of the 15 INDELs were 
still significant after Bonferroni correction (P threshold = 1.03×10-7).  
 
Functional annotations of new regions 
Because the underlying mechanisms of known regions have been well illustrated, 
we performed functional annotations on the four new loci in this study. To explore 
the potential functions of the INDELs, we performed eQTL and differential 
expression analyses based on GTEx lung tissue data and TCGA lung cancer data for 
these four new regions. In GTEx lung eQTL database, we identified a total of 10 
genes that showed significant cis-eQTL results (P value < 0.05), and 5 of them were 
related to cancer in previous studies. INDEL rs58404727 was a lung cis-eQTL for 
HSPA4L, which encodes heat shock protein family A (Hsp70) member 4 like. 
HSPA4L expression was significantly upregulated in lung tumor tissues compared 
with adjacent lung tissues (P = 4.57×10-13; Figure 3). For INDEL rs71450133, its 
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tag SNP rs28435996 was associated with decreased GAPDH, TPI1, USP5 expression 
and increased MLF2 expression. In the differential expression analysis, GAPDH, 
TPI1, USP5 and MLF2 were all significantly upregulated in lung tumor tissues 
compared with adjacent lung tissues (Figure 3). The full results from the cis-eQTL 
and differential expression analyses are presented in Table S4. 
To identify the causal variants for the four INDELs regions, we constructed a 
rank scoring system based on the public functional databases. As shown in Table 3, 
we found that rs5777156, rs71450133 and rs34057993 were related to multiple 
regulatory elements (promoter histone marks, enhancer histone marks and TFBS) in 
multiple tissues or cell lines, while rs58404727 is located in a desert region. 
Furthermore, rs5777156 was located in the promoter histone marks and enhancer 
histone marks in the A549 EtOH 0.02pct lung carcinoma cell line in the ENCODE 
database; rs71450133 also showed enhancer histone marks in the A549 EtOH 
0.02pct lung carcinoma cell line and in NHLF lung fibroblast primary cells in the 
ENCODE database. In the RegulomeDB annotation, the RegulomeDB score for 
rs5777156 was 3a, suggesting that rs5777156 might affect TF binding at the DNase 
peak. Meanwhile, rs71450133 may interact with the VWF and CD9 genes through 
the 3D SNP annotation. The other two INDELs did not show any functional 
evidence in multiple databases. For these four new signals, we also identified seven 
candidate causal SNPs based on the rank scoring system (Table S5). At 1p13.2, a 
non-coding variant, rs12567622 in MAGI3, were predicted as the causal variant. At 
4q28.2, the most plausible target SNP was rs72618844, which also showed an 
enhancer histone mark in the A549 EtOH 0.02pct lung carcinoma cell line. At 
12p13.31, the predicted causal SNPs include rs7304688, which is located in the 
regulatory element site in A549 EtOH 0.02pct lung carcinoma cell line. At 14q22.3, 
the rs10483677 SNP was a predicted causal variant. Further studies will be required 
to determine whether these SNPs are truly causal variants for each locus. 
 
The relationship between INDELs and SNPs 
To understand the effects of the INDELs or SNPs on lung cancer risk, we 
12 
 
examined the relationship between the two types of variations from the same loci. In 
the four known loci, we found that most of the INDELs were in considerable linkage 
disequilibrium (LD) with previously reported risk SNPs (r2: 0.5~1.0; Table S6). 
However, 5 INDELs in the HLA region did not show high LD with known risk SNPs 
(r2 < 0.1). We performed a conditional analysis to determine whether those 5 
INDELs exerted independent effects from known SNPs for each locus. INDEL 
rs145093187 showed an independent signal after adjusting the reported SNPs 
through Bonferroni correction (OR = 0.86, 95CI% = 0.81-0.91, conditional P = 
5.10×10-8), while other the INDELs did not reach the suggestive threshold (Table 
S7). For the new loci, the regional plots provide the LD relationship between the 
INDELs and SNPs at a 1 Mb window (Figure 2). We found that although INDELs 
showed a strong effect on lung cancer risk, there were still SNPs with high LD (r2 > 
0.8) showing a stronger effect. We also conducted conditional analysis on the 
INDELs and top SNPs in each locus. By adding the SNP with the lowest P value 
into the model for each locus, neither the INDEL nor the SNP showed a significant 
signal (Table S7). Meanwhile, we also performed conditional analyses on the four 
candidate causal SNPs and four new INDELs in each locus. When we added the 
candidate causal SNPs to the model, the INDELs showed stronger effects at the 
statistical level. In half of the four conditional analyses, the INDELs remained 
nominally significant (P < 0.05) (Table S8). 
 
Discussion 
In this study, we conducted a genome-wide meta-analysis with 23,202 cases and 
19,048 controls to systematically explore the associations between INDELs and lung 
cancer risk. We identified 19 signals for lung cancer risk, and 4 of them were first 
reported in lung cancer. 
INDEL rs5777156 is an insertion lying in the MAGI3 intron at 1p13.2. MAGI3 
acts as a scaffolding protein at cell-cell junctions, regulating various cellular and 
signaling processes, such as the Ras signaling pathway and PTEN pathway. Previous 
studies showed that MAGI3 could downregulate Wnt/β-catenin signaling, 
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suppressing malignant glioma cell phenotypes [28], and competes with NHERF-2 to 
negatively regulate LPA2 receptor signaling in colon cancer cells [29]. Additionally, 
INDEL rs5777156 and the predicted causal variant were all present in regulatory 
elements, including promoter and enhancer histone marks in a lung carcinoma cell 
line based on the ENCODE database, suggesting that rs5777156 may affect lung 
cancer risk through transcript regulation.  
Our study also identified a new risk locus at 4q28.2 marked by INDEL 
rs58404727 mapping to 65 kb upstream of RP11-184M15.2, which is a lncRNA with 
little functional evidence. However, the predicted causal variant SNP rs72618844 
showed promoter and enhancer histone marks in A549 lung carcinoma cell line. 
INDEL rs58404727 may be a tagging signal at this locus, while rs72618844 affects 
lung cancer risk.  
INDEL rs71450133 is a deletion that maps to 23 kb upstream of PLEKHG6 at 
12p13.31. Genetic variants at 12p13.31 have been shown by previous studies to be 
associated with colorectal cancer risk in East Asians [30]. Although the function of 
PLEKHG6 in tumors is unclear, some studies showed that PLEKHG6 might regulate 
the invasion activity of breast cancer cells [31,32]. In the eQTL analyses, 
rs71450133 was associated with the expression of several genes, and 4 of them were 
tumor related. GAPDH encodes a member of the glyceraldehyde-3-phosphate 
dehydrogenase protein family and can interact with proteins participating in DNA 
repair [33]. USP5, namely ubiquitin specific peptidase 5, plays an important role in 
ubiquitination. USP5 expression has been proven to be associated with several 
cancer types, such as hepatocellular carcinoma, glioblastoma and pancreatic cancer 
[34-36]. Previous studies have shown that USP5 had many cellular targets and 
stabilizes multiple proteins, such as p53 [37]. TPI1, triosephosphate isomerase 1, 
encodes a crucial enzyme in the carbohydrate metabolism, and previous studies have 
shown its expression level might be associated with several cancer types [38,39]. 
Another gene, MLF2 or Myeloid Leukemia Factor 2, is related to myeloid leukemia 
and leukemia, and MLF2 knockdown may reduce tumor initiation and metastasis in 
breast cancer [40]. Functional annotation based on ENCODE suggested that 
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rs71450133 and its high LD SNPs are located in regulatory elements in A549 EtOH 
0.02pct lung carcinoma cell line.  
Another new susceptibility locus, 14q22.3, was marked by INDEL rs34057993, 
which is a deletion located in the intron of non-coding RNA OTX2-AS1, an OTX2 
antisense RNA at 14q22.3. OTX2, which encodes a member of the bicoid subfamily 
of homeodomain-containing transcription factors, has been implicated as a potential 
driver of medulloblastoma tumorigenesis [41,42]. Although rs34057993 and its LD 
SNPs did not show any promoter or enhancer histone marks, genes associated with 
INDEL rs34057993 were cancer-related, it is possible that rs34057993 may act by 
regulating the expression of genes to influence lung cancer risk.  
In this study, we found four novel risk loci for lung cancer, as well as illustrated 
the relationships between INDELs and SNPs. In the reported regions, most of the 
significant INDELs were correlated with previously reported SNPs, especially in 
5p15.33 and 15q25.1. In the HLA region, we found a novel signal that was 
independent of the previously reported SNPs. Considering the complex LD and 
haplotype structure in the HLA region [43], the novel INDEL may be a true 
association. In the new regions, we also observed INDELs that did not harbor the 
lowest P values and showed high LD with nearby SNPs. The effects of the INDELs 
were decreased after adjusting for the top SNP in each region. This suggests that the 
presented SNPs promote more stable effects in both known and new regions. 
However, it is generally assumed that SNPs with the most significant signal usually 
tag causal variants with a small effect. After conducting conditional analysis on 
seven potential causal SNPs, we found that the INDELs in the new loci were still 
nominally significant. Thus, it is possible that the INDELs may also be both causal 
and tagging variants. The combination of these variants with small effects together 
could lead to lung cancer. The functional annotation results confirmed our insights. 
In new region, two INDELs, rs5777156 and rs34057993, showed enhancer histone 
marks in regulatory regions, which may influence enhancer activity in lung cancer. 
Meanwhile, the most significant SNPs in those two regions did not show strong 
functional evidence. This means INDELs could also be a causal variant, which could 
regulate gene expression and affect the risk of lung cancer. The comprehensive 
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annotation of each locus also identified potential causal variants in high LD with the 
INDELs. Interestingly, we noticed that all 19 significant INDELs mapped to the 
non-coding region (intronic or intergenic region). INDELs in the coding region can 
result in frameshift and non-frameshift mutations, which are relatively severe 
mutations and more likely to be observed in Mendelian diseases or tumors [9,11]. 
Overall, the limitation of the present study is that we only evaluated the functional 
evidence from available databases for the identified INDELs, further functional 
experiments are needed to better understand INDEL mechanisms in lung cancer 
carcinogenesis. 
In conclusion, we performed a large-scale case-control study to evaluate 
INDELs and their risk for lung cancer, and four new risk loci at 1p13.2, 4q28.2, 
12p13.31 and 14q22.3 were identified. Our findings indicate that INDELs could be 
potentially functional genetic variants for lung cancer risk.  
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Tables  
 
Table 1. The association between the INDELs in the new regions and lung cancer risk. 
a: The effect allele frequencies of the insertion or deletion in 1000 Genomes EUR samples; 
b: The effect allele frequencies of the insertion or deletion in 1000 Genomes EAS samples; 
c: The OR (95%CI) and P value for the meta-analysis were fixed-effects model;  
INFO.: imputaion quality info.; Het P: P value for heterogeneity test. 
 
 
 
 
 
 
 
 
 
 
Chr. INDEL Gene INS/DEL INFO. Major Minor 
EUR 
a 
EAS b 
Overall Results c 
OR (95%CI) P Het P 
1p13.2 rs5777156 MAGI3 Insertion 0.999 - A 0.24 0.61 0.92 (0.89,0.95) 9.10×10-8 0.837 
4q28.2 rs58404727 RP11-184M15.2 Deletion 0.999 T - 0.02 0.33 1.19 (1.11,1.28) 5.25×10-7 0.191 
12p13.31 rs71450133 PLEKHG6 Deletion 0.986 AA - 0.18 0.38 1.09 (1.05,1.13) 8.83×10-7 0.990 
14q22.3 rs34057993 OTX2-AS1 Deletion 0.975 G - 0.17 0.27 0.90 (0.87,0.94) 7.64×10-8 0.587 
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Table 2. The association between the INDELs in the known regions and lung cancer risk. 
a: The effect allele frequencies of the insertion or deletion in 1000 Genomes EUR samples; 
b: The effect allele frequencies of the insertion or deletion in 1000 Genomes EAS samples; 
c: The OR(95%CI) and P value for the meta-analysis were fixed-effects model;  
Het P, heterogeneity P value. 
 
Chr. INDEL Gene INS/DEL Major Minor EUR a EAS b 
Overall Results c 
OR (95%CI) P Het P 
5p15.33 rs34218850 TERT Deletion C - 0.34 0.19 1.14 (1.11,1.18) 7.98×10-18 0.097 
6p21.32 rs200675567 HLA-DQA1 Deletion C - 0.11 0.16 0.90 (0.86,0.96) 4.03×10-7 0.412 
6p21.32 rs9279532 NOTCH4 Deletion G - 0.12 0.05 1.11 (1.07,0.94) 2.77×10-7 0.588 
6p21.33 rs550239034 POU5F1 Deletion TT - 0.25 0.46 0.92 (0.89,0.95 2.12×10-7 0.055 
6p21.33 rs549219764 HCP5 Deletion G - 0.20 0.02 1.11 (1.07,1.15) 2.01×10-9 0.091 
6p22.1 rs9280949 RPP21 Insertion - T 0.09 0.06 1.16 (1.11,1.22) 2.53×10-10 0.468 
6p22.1 rs139089584 LINC00533 Insertion - TTTG 0.29 0.54 0.92 (0.89,0.95) 2.40×10-7 0.145 
6p22.1 rs34832458 HLA-G Insertion - T 0.39 0.24 0.92 (0.89,0.94) 1.29×10-9 0.077 
6p22.1 rs374787445 HLA-F-AS1 Deletion C - 0.18 0.23 1.11 (1.07,1.15) 6.56×10-9 0.323 
6p22.2 rs145093187 BTN2A1 Insertion - T 0.12 0.05 0.87 (0.83,0.91) 9.44×10-9 0.478 
11q23.3 rs139157129 MPZL2 Deletion A - 0.48 0.43 0.93 (0.90,0.95) 1.90×10-7 0.864 
15q25.1 rs577626090 CHRNA5 Deletion AAAAG - 0.37 0.03 1.29 (1.25,1.33) 9.91×10-64 0.945 
15q25.1 rs138784116 CHRNB4 Deletion AGG - 0.37 0.14 0.89 (0.86,0.92) 4.65×10-14 0.655 
15q25.1 rs143284856 MORF4L1 Insertion - TT 0.47 0.12 1.11 (1.08,1.14) 1.29×10-12 0.732 
15q25.1 rs61655864 CHRNA5 Deletion A - 0.29 0.77 0.81 (0.79,0.84) 6.24×10-37 0.068 
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Table 3. Comprehensive functional annotations for the INDELs in the new regions.  
Chr. SNP Region INS/DEL Gene Enhancer a Promoter a TFBS a 3D Score a 3D Interaction Gene a CADD b RegulomeDB c PINES d 
1p13.2 rs5777156 Intronic Insertion MAGI3 6 1 2 2.300 - 4.264 3a 0.243 
4q28.2 rs58404727 Intergenic Deletion RP11-184M15.2 0 0 0 1.820 - 3.743 7 0.499 
12p13.31 rs71450133 Intergenic Deletion PLEKHG6 11 0 0 3.810 VWF, CD9 6.315 6 0.089 
14q22.3 rs34057993 Intronic Deletion OTX2-AS1 18 1 0 6.960 - 1.310 7 0.061 
a: Enhancer, promoter and TFBS were obtained from 3DSNP based on the ENCODE database. 3DSNP was the overall function score and the interacting gene reflected the three-dimensional 
interaction genes. 
b: CADD was used to evaluate the relative deleteriousness. 
c: RegulomeDB was used to identify DNA features and regulatory elements in non-coding regions in the human genome. 
d: PINES provided a powerful in silico method to prioritize and finely map the functional non-coding variants. SNPs with lower P values indicated more abundant functions. 
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Figure Titles and Legends 
 
 
 
Figure 1. Manhattan plots of INDEL associations with lung cancer risk.  
The x-axis represents the chromosomal location and the y-axis represents the -log10 
(P value). Red, previously known loci and blue, new loci identified in this analysis. 
The red line denotes the Bonferroni correction significance (P = 1.03 × 10-7) and the 
green line denotes the suggestive significance (P < 1.0×10-6). 
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Figure 2. Regional plots of the 4 new regions, including (A) Chr1p13.2: 
rs5777156, (B) Chr4q28.2: rs58404727, (C) Chr12p13.31: rs71450133, and (D) 
Chr14q22.3: rs34057993. 
 
The x-axis shows the chromosomal positions and the left y-axis shows the –log10 p 
values from an association test. The INDELs are shown as purple diamonds. The 
colors of the dots indicate the LD relationship between the most significantly 
associated INDELs and the remaining SNPs in the 500 kb region. The right y-axis 
shows the recombination rate between the SNPs. The genes within the 
region-of-interest are annotated with arrows indicating the direction of transcription. 
 
 
Figure 3. eQTL and differential expression of the INDELs among GTEx lung 
tissue and TCGA lung cancer data. 
